The US medicines regulator has established a new Center for Clinical Trial Innovation (C3TI).
Operated by the agency’s Center for Drug Evaluation and Research (CDER), the mission of the division will be to promote clinical trial innovation through enhanced communication and collaboration.
The US Food and Drug Administration, headed by Commissioner Robert Califf, is seeking to take advantage of innovations in trial design, with new collaborations both within and outside of the agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze